C H Kohne

Suggest Changes
Learn More
3576 Background: In the CRYSTAL and OPUS studies, adding cetuximab to first-line chemotherapy (CT) improved clinical benefit in patients (pts) with KRAS wild-type (wt) mCRC. R0 resection of(More)
PURPOSE Colorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it(More)
3634 Background: Study 314 was a phase II, single-arm, multicenter study designed to assess the efficacy/safety by KRAS tumor status of first-line pmab plus FOLFIRI in pts with mCRC. Here, we(More)
96 Background: In the CRYSTAL and OPUS studies, adding cetuximab (cet) to first-line chemotherapy (CT) improved clinical benefit in patients (pts) with KRAS wild-type (wt) metastatic colorectal(More)